1. Home
  2. AEVA vs PBYI Comparison

AEVA vs PBYI Comparison

Compare AEVA & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AEVA

Aeva Technologies Inc.

HOLD

Current Price

$27.69

Market Cap

1.3B

ML Signal

HOLD

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

HOLD

Current Price

$7.20

Market Cap

343.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEVA
PBYI
Founded
2019
2010
Country
United States
United States
Employees
239
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
343.9M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
AEVA
PBYI
Price
$27.69
$7.20
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$26.50
N/A
AVG Volume (30 Days)
2.7M
250.7K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$27,685,000.00
Revenue This Year
$85.37
N/A
Revenue Next Year
$132.72
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.83
$3.03
52 Week High
$38.79
$7.90

Technical Indicators

Market Signals
Indicator
AEVA
PBYI
Relative Strength Index (RSI) 68.56 50.44
Support Level $12.36 $7.09
Resistance Level N/A $7.25
Average True Range (ATR) 2.91 0.26
MACD 0.84 0.00
Stochastic Oscillator 86.94 61.17

Price Performance

Historical Comparison
AEVA
PBYI

About AEVA Aeva Technologies Inc.

Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The 4D LiDAR sensors are designed to detect both velocity and position, supporting perception and decision-making in automated systems. The company operates in North America, EMEA, and Asia. The company's revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services. Geographically, it derives the majority of its revenue from North America.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: